Nimbus discovery and Proteros enter into privileged X-RAY crystallography partnership agreement

Martinsried, Germany, November 12, 2012. Proteros biostructures GmbH ("Proteros") today announced that it has executed a Privileged Partnership Agreement with Nimbus Discovery LLC (Nimbus), Cambridge, Massachusetts, USA. This partnership will accelerate drug discovery efforts against a growing pipeline of medically important targets.

Nimbus joins a select number of prestigious pharmaceutical and biotechnology companies that have entered into Privileged Partnership Agreements with Proteros. Privileged Partners are able to preferentially access Proteros’ new Gallery Structures and Gallery Assays, technologies and extensive in-house expertise to accelerate structure-based drug discovery efforts.

Proteros continues to grow its analytical services business through innovative business models and services. The service business consists of X-ray protein crystallography (expanding catalogue of Gallery Structure targets ready-to-use for structure analysis to gene-to-structure projects for the analysis of challenging targets), kinetic/thermodynamic compound profiling (generation of information allowing the discovery of drugs with desired residence time, kinetic selectivity and thermodynamic profile) and custom protein supply. In response to customer requests Proteros integrates these services with medicinal chemistry and a fragment library of over 30,000 novel target directed molecules to offer integrated lead discovery projects.

Jonathan Montagu, Vice President, Business Development and Operations at Nimbus commented, “Our cutting-edge computational platform relies heavily upon high quality x-ray structure data. Hence, our current collaboration with Proteros has been instrumental in our success with previously inaccessible targets. This expanded partnership is a logical progression of how we are integrating leading edge technologies to create a new model for drug discovery.”

Cony D’Cruz, Chief Business Officer and President, Proteros, US Inc. added, “We are excited to expand our collaboration with Nimbus. The relationship has been very productive and we look forward to continuing to support Nimbus’ innovative and proven discovery platform.”

About Nimbus
Nimbus Discovery, a biotechnology company, harnesses cutting-edge computational technologies to uncover breakthroughs in small molecule pharmacology. We focus on medically important and highly sought-after disease targets that have proven inaccessible to traditional industry approaches. Our robust pre-clinical pipeline includes novel agents for the treatment of cancer, metabolic disease and inflammation. Nimbus is organized as a constellation of small, nimble teams of experienced drug-hunters deployed across program-focused subsidiary companies. Each team is freed from conventional barriers to scientific success, chartered to create solutions, and geared for program asset deals with leading pharmaceutical companies. Founded in 2009, Nimbus partnered with Schrödinger to invent and apply a physics-based approach that establishes a new standard for rational drug design. Nimbus is backed by world-class life science investors; including Atlas Venture, SR One, Lilly Ventures and Gates Ventures. For more information please visit www.nimbusdiscovery.com.

About Proteros
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and fragment-based lead generation incorporating protein structure inspired compound and fragment libraries. The platform enables "knowledge driven lead engineering" to accelerate and improve protein structure analysis and structure-based drug discovery towards kinetically and thermodynamically optimized lead molecules. Proteros complements its clients' internal capabilities with external expertise and access to flexible resources. Proteros currently provides services to more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. Proteros US, Inc. is a wholly owned subsidiary of Proteros established to serve the growing customer base in North America.

Contact:
Nimbus Discovery LLC
Jonathan Montagu
Vice President, Business Development & Operations
25 First Street, Suite 404
Cambridge, MA 02141
USA
Phone: +1 (617) 588-2600
Fax: +1 (617) 231-0652
Email: info@nimbusdiscovery.com
Web: www.nimbusdiscovery.com

Proteros biostructures GmbH Cony D’Cruz
Chief Business Officer
Bunsenstrasse 7a
D-82152 Martinsried
Germany
Phone: +49 (0) 89 7007 61 - 0
Fax: +49 (0) 89 7007 61 - 15
E-Mail: business@proteros.com
Web: www.proteros.com